Bayer Enters AI Partnership With Exscientia for Cardiovascular, Oncology Drug Discovery

   By Kim Richters

Bayer AG (BAYN.XE) said Thursday that it has entered a research collaboration with pharma-tech company Exscientia Ltd. to use artificial intelligence in cardiovascular and oncology drug discovery.

The German pharmaceutical and chemical giant said the companies will focus on early-stage research and use artificial intelligence to predict potential drug molecules, possibly accelerating drug discovery.

"Exscientia's AI-driven drug discovery technology provides novel chemical matter for difficult-to-address targets and could identify novel drug candidates more efficiently through less optimization cycles," Bayer said.

As part of the three-year agreement, the U.K.-based Exscientia may get up to 240 million euros ($267.1 million) as well as sales royalties, while Bayer will own the rights to lead structures generated during the collaboration.

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

January 09, 2020 07:52 ET (12:52 GMT)

Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024